0
0
0
No Tax Breaks for Drug Ads Act
12/30/2022, 3:49 AM
Summary of Bill HR 6392
Bill 117 hr 6392, also known as the No Tax Breaks for Drug Ads Act, is a piece of legislation introduced in the US Congress. The main purpose of this bill is to eliminate tax deductions for expenses related to advertising prescription drugs.
Under current tax laws, pharmaceutical companies are able to deduct the costs of advertising their prescription drugs as a business expense. This bill seeks to change that by disallowing these deductions, effectively making it more expensive for drug companies to advertise their products.
Proponents of the bill argue that eliminating tax breaks for drug ads will help reduce the overall cost of prescription drugs for consumers. They believe that by making it more costly for pharmaceutical companies to advertise, they will be less inclined to spend large amounts of money on marketing and, as a result, drug prices may decrease. Opponents of the bill, on the other hand, argue that eliminating tax deductions for drug ads could have negative consequences for the pharmaceutical industry. They believe that this change could stifle innovation and hinder the ability of drug companies to effectively market their products to consumers. Overall, the No Tax Breaks for Drug Ads Act is a controversial piece of legislation that aims to address the issue of high prescription drug prices in the US. It remains to be seen whether or not this bill will gain enough support to pass in Congress and become law.
Under current tax laws, pharmaceutical companies are able to deduct the costs of advertising their prescription drugs as a business expense. This bill seeks to change that by disallowing these deductions, effectively making it more expensive for drug companies to advertise their products.
Proponents of the bill argue that eliminating tax breaks for drug ads will help reduce the overall cost of prescription drugs for consumers. They believe that by making it more costly for pharmaceutical companies to advertise, they will be less inclined to spend large amounts of money on marketing and, as a result, drug prices may decrease. Opponents of the bill, on the other hand, argue that eliminating tax deductions for drug ads could have negative consequences for the pharmaceutical industry. They believe that this change could stifle innovation and hinder the ability of drug companies to effectively market their products to consumers. Overall, the No Tax Breaks for Drug Ads Act is a controversial piece of legislation that aims to address the issue of high prescription drug prices in the US. It remains to be seen whether or not this bill will gain enough support to pass in Congress and become law.
Congressional Summary of HR 6392
No Tax Breaks for Drug Ads Act
This bill prohibits a tax deduction for expenses relating to direct-to-consumer advertising of prescription drugs.
Direct-to-consumer advertising is any dissemination, by or on behalf of a sponsor of a prescription drug product, of an advertisement that is in regard to the drug product and primarily targeted to the general public.
Read the Full Bill
Current Status of Bill HR 6392
Bill HR 6392 is currently in the status of Bill Introduced since January 13, 2022. Bill HR 6392 was introduced during Congress 117 and was introduced to the House on January 13, 2022. Bill HR 6392's most recent activity was Referred to the House Committee on Ways and Means. as of January 13, 2022
Bipartisan Support of Bill HR 6392
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
6Democrat Cosponsors
6Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 6392
Primary Policy Focus
TaxationAlternate Title(s) of Bill HR 6392
No Tax Breaks for Drug Ads Act
No Tax Breaks for Drug Ads Act
To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs.
Comments
Sponsors and Cosponsors of HR 6392
Latest Bills
National Defense Authorization Act for Fiscal Year 2026
Bill S 1071December 13, 2025
Enduring Justice for Victims of Trafficking Act
Bill S 2584December 13, 2025
Technical Corrections to the Northwestern New Mexico Rural Water Projects Act, Taos Pueblo Indian Water Rights Settlement Act, and Aamodt Litigation Settlement Act
Bill S 640December 13, 2025
Incentivizing New Ventures and Economic Strength Through Capital Formation Act of 2025
Bill HR 3383December 13, 2025
BOWOW Act of 2025
Bill HR 4638December 13, 2025
Northern Mariana Islands Small Business Access Act
Bill HR 3496December 13, 2025
Wildfire Risk Evaluation Act
Bill HR 3924December 13, 2025
Energy Choice Act
Bill HR 3699December 13, 2025
ESTUARIES Act
Bill HR 3962December 13, 2025
Improving Interagency Coordination for Pipeline Reviews Act
Bill HR 3668December 13, 2025



